EMA Recommends Six New Oncology Indications in January and February

Since the beginning of the year, the European Medicines Agency (EMA) has issued six positive opinions recommending new indications for treatments in oncology, with a heavy focus on new treatments for lung cancer. These agents have previously been approved by the United States (US) Food and Drug Administration (FDA). Final approval in the European Union […]

Read More

Increased Toxicity When PD-(L)1 Inhibitor Is Followed by Osimertinib

The treatment landscape for advanced non-small cell lung cancer (NSCLC) is constantly changing. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is standard of care for EGFR-mutant NSCLC, and the indications for PD-(L)1 targeting immune checkpoint inhibitors are rapidly expanding and include metastatic (first-line and beyond) and locally advanced disease. With the introduction of multiple novel […]

Read More

Pertuzumab and Trastuzumab Combo Active For HER2-Positive mCRC

For patients with HER2-overexpressed or -amplified breast or gastric cancer, treatment with HER2-targeting agents is standard of care.  HER2 amplification/overexpression in metastatic colorectal cancer (mCRC) is rare (approximately 2% to 6% of patients). This low frequency of HER2 alterations has constrained investigations of HER2-targeted therapies in mCRC. However, based on the activity of HER2-targeted combinations […]

Read More

Immune Checkpoint Inhibitors in Patients With NSCLC and Brain Metastases

Immune checkpoint inhibitors (ICI) targeting PD-1 and PD-L1 are a standard treatment for metastatic non-small cell lung cancer (NSCLC) across multiple lines of therapy for patients who do not possess targetable driver mutations. While as many as 40% of patients with advanced NSCLC will develop brain metastases during the course of their disease, patients with […]

Read More

No Value for Lymphadenectomy in Advanced Ovarian Cancer

Most patients with ovarian cancer are diagnosed in an advanced stage. The standard of care for these patients is maximal cytoreductive surgical debulking, followed by systemic treatment including platinum-based chemotherapy and targeted therapies (eg, bevacizumab, olaparib maintenance in patients harboring BRCA mutations). The goal of primary surgical cytoreduction is removal of as much of the […]

Read More

New Androgen Receptor Inhibitor for Nonmetastatic Prostate Cancer

Delaying the development of metastases is a major goal in the management of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), as these patients typically have poor outcomes and short survival once their disease becomes metastatic. Currently, two androgen receptor (AR) inhibitors apalutamide and enzalutamide are approved for patients with nmCRPC, based on results of the […]

Read More

Four Oncology Indications Approved by FDA in January and February

Subcutaneous Trastuzumab Now Available in US for HER2- Positive Breast Cancer. The FDA approved trastuzumab and hyaluronidase-oysk injection (Herceptin Hylecta™, Genentech), a subcutaneous (SC) formulation of trastuzumab, for treatment of patients with HER2-positive breast cancer. Approval was based on results from the HannaH and SafeHER studies, which compared trastuzumab and hyaluronidase-oysk to standard intravenous (IV) […]

Read More